Immunovant (IMVT) Stock Overview
A clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IMVT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Immunovant, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.88 |
| 52 Week High | US$27.69 |
| 52 Week Low | US$12.72 |
| Beta | 0.56 |
| 1 Month Change | 15.27% |
| 3 Month Change | 71.54% |
| 1 Year Change | 3.07% |
| 3 Year Change | 55.38% |
| 5 Year Change | -45.51% |
| Change since IPO | 170.15% |
Recent News & Updates
Recent updates
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
Dec 12We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jul 22
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Mar 19Immunovant, Inc.'s (NASDAQ:IMVT) Intrinsic Value Is Potentially 97% Above Its Share Price
Feb 06Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study
Dec 27Immunovant: Switching Lead Candidates Increases Risk
Oct 14Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive
Jun 27Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Apr 04Immunovant: An Intriguing And Developing Story
Jan 25Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
Oct 17Immunovant stock down on raising $75M though equity capital
Oct 04Shareholder Returns
| IMVT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.4% | 2.6% | 2.6% |
| 1Y | 3.1% | 25.9% | 14.2% |
Return vs Industry: IMVT underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: IMVT underperformed the US Market which returned 14.2% over the past year.
Price Volatility
| IMVT volatility | |
|---|---|
| IMVT Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMVT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMVT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 362 | Eric Venker | immunovant.com |
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York.
Immunovant, Inc. Fundamentals Summary
| IMVT fundamental statistics | |
|---|---|
| Market cap | US$5.45b |
| Earnings (TTM) | -US$464.69m |
| Revenue (TTM) | n/a |
Is IMVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMVT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$464.69m |
| Earnings | -US$464.69m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMVT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 22:38 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunovant, Inc. is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |